About Careers MedBlog Contact us
Medindia LOGIN REGISTER
Advertisement

Oxybutynin- An Urinary Incontinence Drug Reduces Hot Flashes In Women

by Rishika Gupta on December 8, 2018 at 8:16 PM
Font : A-A+

 Oxybutynin- An Urinary Incontinence Drug Reduces Hot Flashes In Women

Oxybutynin could serve as the ultimate drug for treating hot flashes in breast cancer patients especially those who are unable to take hormone replacement therapy.

Research led by oncologists Roberto Leon-Ferre, M.D. and Charles Loprinzi, M.D. of Mayo Clinic has found that the drug oxybutynin helps to reduce the frequency and intensity of hot flashes in women who are unable to take hormone replacement therapy, including breast cancer survivors. These findings were presented at the 2018 San Antonio Breast Cancer Symposium.

Advertisement


"Hot flashes are a common symptom of menopause and can be even more severe in breast cancer survivors than they are in the general population," says Dr. Leon-Ferre.

He says several factors contribute to the increased severity of hot flashes in breast cancer survivors including exposure to chemotherapy, which may bring on early menopause; the use of anti-estrogen drugs, such as tamoxifen or aromatase inhibitors; and the use of medications or procedures to suppress the function of the ovaries.
Advertisement

Hormone replacement therapy, which is sometimes used to treat hot flashes, is generally not recommended for breast cancer survivors. "Hot flashes not only impact a patient's quality of life, but they are also associated with patients prematurely discontinuing breast cancer treatment, which may increase the risk of breast cancer recurrence and mortality," says Dr. Leon-Ferre. "It is important for physicians to have effective options to treat hot flashes."

Dr. Leon-Ferre says previous research had suggested that hot flashes may be relieved with oxybutynin, an anticholinergic agent which interferes with the activity of a neurotransmitter in the brain and the peripheral nervous system. The drug is most commonly used to treat urinary incontinence.

In this study, researchers sought to determine whether oxybutynin was more effective than placebo in treating hot flashes and in improving patients' quality of life. The researchers enrolled 150 women who had experienced at least 28 hot flashes per week over more than a month, and who were bothered enough by them to want medication. Sixty-two percent of the women were on tamoxifen or an aromatase inhibitor for the duration of the study. There were three arms in the trial with patients in two arms receiving different dosages of oxybutynin and patients in the third arm receiving a placebo.

The study found that patients on both oxybutynin doses saw decreases in hot flashes compared to the women who took the placebo. The women in both oxybutynin arms also reported decreased interference of hot flashes in their work, social activities, leisure activities, sleep, and improvement in their overall quality of life.

"This study, in addition to previously published work in this area, establishes that oxybutynin is an effective drug for treatment of hot flashes in patients who have relative or absolute contraindications to hormone-based therapy," says Dr. Leon-Ferre. "We were surprised by the rapidity of the response and the magnitude of the effect, considering the relatively low dose of the drug."

He says that oxybutynin does not interfere with the metabolism of tamoxifen, which is an important consideration for breast cancer survivors, as some of the most effective non-hormonal treatments for hot flashes (e.g., antidepressants) are thought to potentially decrease the efficacy of tamoxifen.

Dr. Leon-Ferre said that since oxybutynin is already available for other indications, physicians could potentially prescribe it off-label. However, he says the study did not address long-term toxicities of oxybutynin.

Previous research has indicated that long-term use of this type of drug may be associated with cognitive decline. These possible side effects should be further researched and taken into consideration when physicians counsel patients.

Source: Eurekalert
Advertisement

Advertisement
Advertisement

Recommended Reading

Latest Women Health News

Risk Alert: Women on Oral Estrogen Hormones Face Higher Risk of Hypertension
Women over 45 years old taking estrogen pills have a higher likelihood of developing high blood pressure compared to those using transdermal or vaginal formulations.
Chest Pain Medication Helps Treat Hot Flashes
The new study assessed the beneficial effects of nitroglycerin patches in treating hot flashes in postmenopausal women.
 Does Voluntarily Adding Folic Acid to Corn Masa Flour Prevent Birth Defects?
A new study investigated the rate of neural tube defects in predominantly Hispanic-populated women before and after the voluntary fortification of corn masa flour with folic acid.
Women! When is the Right Time to Get a Mammogram?
Experts suggest that getting regular mammograms at the age of 40 can help women prevent breast cancer.
 Finding the Best Tool for Assessing Osteoporosis Fracture Risk After Menopause
The commonly used Fracture Risk Assessment Tool (FRAX) is not useful for shared clinical decision-making regarding osteoporosis screening in younger postmenopausal women.
View All
This site uses cookies to deliver our services.By using our site, you acknowledge that you have read and understand our Cookie Policy, Privacy Policy, and our Terms of Use  Ok, Got it. Close
×

Oxybutynin- An Urinary Incontinence Drug Reduces Hot Flashes In Women Personalised Printable Document (PDF)

Please complete this form and we'll send you a personalised information that is requested

You may use this for your own reference or forward it to your friends.

Please use the information prudently. If you are not a medical doctor please remember to consult your healthcare provider as this information is not a substitute for professional advice.

Name *

Email Address *

Country *

Areas of Interests